Simulation of Human Gentamicin Pharmacokinetics in an Experimental Enterococcus faecalis Endocarditis Model

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 11, 2003, Pages 3663-3666

  Dubé, Laurent ^a,b   Caillon, Jocelyne ^a   Gras Le Guen, Christèle ^a   Jacqueline, Cédric ^a   Kergueris, Marie France ^c   Granry, Jean Claude ^b   Potel, Gilles ^a   Bugnon, Denis ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; FEMALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SIMULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; RABBITS;

EID: 0242290926     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.11.3663-3666.2003     Document Type: Article

References (36)

1. Andes, D., and W. A. Craig. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
2. Bonten, M. J., F. H. van Tiel, S. van der Geest, E. E. Stobberingh, and C. A. Gaillard. 1993. Enterococcus faecalis pneumonia complicating topical antimicrobial prophylaxis. N. Engl. J. Med. 328:209-210.
3. Bonten, M. J. M., C. A. Gaillard, F. H. van Tiel, S. van der Geest, and E. E. Stobberingh. 1995. Colonization and infection with Enterococcusfaecalis in intensive care units: the role of antimicrobial agents. Antimicrob. Agents Chemother. 39:2783-2786.
4. Bugnon, D., G. Potel, J. Caillon, D. Baron, H. B. Drugeon, P. Feigel, and M. F. Kergueris. 1998. In vivo simulation of human pharmacokinetics in the rabbit. Bull. Math. Biol. 60:545-567.
5. Bugnon, D., G. Potel, Y. Q. Xiong, J. Caillon, M. F. Kergueris, P. Le Conte, D. Baron, and H. Drugeon. 1996. In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model. Antimicrob. Agents Chemother. 40:1164-1169.
6. Chow, J. W. 2000. Aminoglycoside resistance in enterococci. Clin. Infect. Dis. 31:586-589.
7. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
8. Curl, J. L., and J. S. Curl. 1988. Pharmacokinetics of gentamicin in laboratory rabbits. Am. J. Vet. Res. 49:2065-2067.
9. Durack, D. T., and P. B. Beeson. 1972. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br. J. Exp. Pathol. 53:44-49.
10. Fantin, B., S. Ebert, J. Leggett, B. Volgeman, and W. A. Craig. 1990. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. J. Antimicrob. Chemother. 27:829-836.
11. Gavalda, J., P. J. Cardona, B. Almirante, J. A. Capdevila, M. Laguarda, L. Pou, E. Crespo, C. Pigrau, and A. Pahissa. 1996. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob. Agents Chemother. 40:173-178.
12. Gavalda, J., P. López, T. Martin, X. Gomis, J. L. Ramirez, C. Azuaje, B. Almirante, and A. Pahissa. 2002. Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis. Antimicrob. Agents Chemother. 46:378-384.
13. Gerber, A. U., H. P. Brugger, C. Feller, T. Stritzko, and B. Stalder. 1986. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J. Infect. Dis. 153:90-97.
14. Gerber, A. U., T. Stritzko, C. Segessenmann, and B. Stalder. 1990. Simulation of human pharmacokinetic profiles in mice, and impact on antimicrobial efficacy of netilmicin, ticarcillin and ceftazidime in the peritonitis-septicemia model. Scand. J. Infect. Dis. Suppl. 74:195-203.
15. Kirkwood, J. K., and J. Merriam. 1990. Variation in plasma half life of gentamicin between species in relation to body weight and taxonomy. Res. Vet. Sci. 49:160-165.
16. Leclercq, R., and J. Duval. 1995. Activité bactéricide des associations de ticacilline-acide clavulanique ou d'autres β-lactamines (amoxicilline, piperacilline-tazobactam, ticarcilline) avec la gentamicine vis-à-vis des Enterococcus faecalis et E. faecium. Pathol. Biol. (Paris) 43:245-252.
17. Lefort, A., M. Arthur, L. Garry, C. Carbon, P. Courvalin, and B. Fantin. 2000. Bactericidal activity of gentamicin against Enterococcusfaecalis in vitro and in vivo. Antimicrob. Agents Chemother. 44:2077-2080.
18. López, P., J. Gavalda, M. T. Martin, B. Almirante, X. Gomis, C. Azuaje, N. Borrell, L. Pou, V. Falcó, C. Pigrau, and A. Pahissa. 2001. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob. Agents Chemother. 45:1387-1393.
19. Marangos, M. N., D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1997. Influence of gentamicin dosing interval on the efficacy of penicillin-containing regimens in experimental Enterococcus faecalis endocarditis. J. Antimicrob. Chemother. 39:519-522.
20. Martin-Jimenez, T., and J. E. Riviere. 2001. Mixed effects modeling of the disposition of gentamicin across domestic animal species. J. Vet. Pharmacol. Ther. 24:321-332.
21. Meunier, F., P. Van der Auwera, H. Schmitt, V. de Maertelaer, and J. Klastersky. 1987. Pharmacokinetics of gentamicin after i.v. infusion or i.v. bolus. J. Antimicrob. Chemother. 19:225-231.
22. Mizen, L., G. Woodnutt, I. Kernutt, and E. J. Catherall. 1989. Simulation of human serum pharmacokinetics of ticarcillin-clavulanic acid and ceftazidime in rabbits, and efficacy against experimental Klebsiella pneumoniae meningitis. Antimicrob. Agents Chemother. 33:693-699.
23. Moellering, R. C. 2000. Enterococcus species, Streptococcus bovis, and Leuconostoc species, p. 2147-2156. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
24. National Committee for Clinical Laboratory Standards. 1992. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. Patterson, J. E., A. H. Sweeney, M. Simms, N. Carley, R. Mangi, J. Sabetta, and R. W. Lyons. 1995. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 74:191-200.
26. Perlman, B. B., and L. R. Freedman. 1971. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44:206-213.
27. Potel, G., J. Caillon, B. Fantin, J. Raza, F. Le Gallou, J.-Y. Lepage, P. Le Conte, D. Bugnon, D. Baron, and H. Drugeon. 1991. Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation. Antimicrob. Agents Chemother. 35:111-116.
28. Potel, G., J. Caillon, F. Le Gallou, D. Bugnon, P. Le Conte, J. Raza, J.-Y. Lepage, D. Baron, and H. Drugeon. 1992. Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis. Antimicrob. Agents Chemother. 36:744-750.
29. Riviere, J. E., T. Martin-Jimenez, S. F. Sundlof, and A. L. Craigmill. 1997. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J. Vet. Pharmacol. Ther. 20:453-463.
30. Sullam, P. M., M. G. Täuber, C. J. Hackbarth, and M. A. Sande. 1985. Antimicrobial activity of gentamicin in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 27:224-226.
31. Swenson, C. E., K. A. Stewart, J. L. Hammett, W. E. Fitzsimmons, and R. S. Ginsberg. 1990. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob. Agents Chemother. 34:235-240.
32. Tailor, S. A., E. M. Bailey, and M. J. Rybak. 1993. Enterococcus, an emerging pathogen. Ann. Pharmacother. 27:1231-1242.
33. Tam, V. H., P. S. Mckinnon, D. P. Levine, S. M. Brandel, and M. J. Rybak. 2000. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. Pharmacotherapy 20:1116-1119.
34. Vazquez, J., M. B. Perri, L. A. Thal, S. A. Donabedian, and M. J. Zervos. 1993. Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits. J. Antimicrob. Chemother. 32:715-721.
35. Wiedemann, B., and H. Grimm. 1996. Susceptibility to antibiotics: species incidence and trends, p. 900-1168. In V. Lorian (ed.). Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, Md.
36. Woodnutt, G., V. Berry, and L. Mizen. 1992. Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infections. Antimicrob. Agents Chemother. 36:1427-1431.